Relating to regulation of pharmacy benefit managers
Senate Bill 852 would amend West Virginia’s Pharmacy Audit Integrity Act to impose additional rules on pharmacy benefit managers (PBMs) governing how they reimburse pharmacies and how they calculate patient cost sharing at the point of sale. The bill generally requires PBMs to reimburse pharmacies and pharmacists at no less than the national average drug acquisition cost (or, if unavailable, wholesale acquisition cost) plus a $10.49 dispensing fee, while also prohibiting reimbursement below what the PBM pays itself or an affiliate for the same drug or service. It also bars PBMs from imposing certain fees, retroactive charges, discriminatory network practices, or reimbursement methods tied to patient outcomes unless those metrics are disclosed and agreed to in advance.
The bill contains several provisions aimed at protecting 340B entities and patients who obtain drugs through those entities. It prohibits PBMs from reimbursing 340B pharmacies at lower rates than similarly situated non-340B pharmacies, from imposing extra burdens or administrative requirements on 340B claims, and from interfering with a patient’s choice to use a 340B entity. These protections are extended to the West Virginia Public Employees Insurance Agency and, in some circumstances, Medicaid managed care organizations, while preserving the state Medicaid program’s ability to prevent duplicate discounts.
SB852 also changes how insured patients’ out-of-pocket costs are calculated. It requires cost sharing to be based on a price reduced by at least 100% of rebates, and it limits point-of-sale payment to the lesser of the plan’s cost share or the cash price for the prescription. If the cash price is lower, that amount must be treated as payment in full. The bill further directs the insurance commissioner to oversee reimbursement disputes, order restitution for monetary losses caused by violations, and receive confidential PBM reimbursement methodologies for maximum allowable cost appeals.
The overall sentiment reflected by the bill text is strongly consumer- and pharmacy-protective, with a clear policy preference for transparency, higher pharmacy reimbursement, and lower patient cost sharing. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate, support, or opposition from the legislative process in the supplied materials.
The main points of contention likely involve the financial impact on PBMs, insurers, and health plans, since the bill would raise minimum reimbursement levels, restrict PBM revenue practices, and require more rebate pass-through at the point of sale. Another likely area of dispute is the treatment of 340B entities and the bill’s limits on PBM network and claims-processing practices, which could be viewed as necessary anti-discrimination protections by supporters and as operational or cost burdens by opponents.
SB852 would substantially expand state regulation of PBMs by setting minimum pharmacy reimbursement standards, restricting fees and spread-pricing practices, protecting 340B pharmacies from discriminatory treatment, and requiring more favorable point-of-sale cost-sharing calculations for insured patients. It would affect PBMs, pharmacies, pharmacists, insurers, the Public Employees Insurance Agency, and certain Medicaid managed care arrangements, while also giving the insurance commissioner authority to enforce compliance and order restitution. The bill would amend West Virginia Code §33-51-9 and would likely increase compliance obligations and potentially increase drug benefit costs for PBMs and health plans.
No committee discussion or vote history was provided, so there is no recorded legislative sentiment to summarize from the supplied materials. Based on the bill text alone, the measure appears designed to be favorable to pharmacies and consumers by increasing reimbursement floors, limiting PBM practices, and lowering patient out-of-pocket costs. The absence of recorded debate prevents a reliable assessment of support or opposition from legislators.
The most likely areas of contention are the bill’s minimum reimbursement mandate, the prohibition on PBMs reimbursing themselves or affiliates at higher rates than outside pharmacies, and the restrictions on fees, retroactive charges, and outcome-based reimbursement. PBMs and insurers may object that these provisions reduce flexibility and increase costs, while pharmacies and 340B entities are likely to support them as protections against underpayment and discriminatory treatment. The point-of-sale rebate pass-through and cash-price payment-in-full provisions may also be disputed because they alter plan design and how cost sharing is calculated.